Σύγκριση μεθόδων
Εξετάστε τις επιλεγμένες μεθόδους δίπλα-δίπλα· οι γραμμές που διαφέρουν επισημαίνονται.
| Πληθυσμιακή Φαρμακοδυναμική Μοντελοποίηση× | Φαρμακοκινητική Βασισμένη στη Φυσιολογία× | |
|---|---|---|
| Πεδίο | Φαρμακολογία | Φαρμακολογία |
| Οικογένεια | Process / pipeline | Process / pipeline |
| Έτος προέλευσης≠ | 1992 | 1997 |
| Δημιουργός≠ | Lewis Sheiner and Stephen Roush | Ivan Nestorov |
| Τύπος≠ | dose-response modeling | predictive modeling |
| Θεμελιώδης πηγή≠ | Dahlström, B., & Nyberg, L. (1993). Population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 24(1), 45-57. link ↗ | Nestorov, I. (1997). Sensitivity analysis of pharmacokinetic and pharmacodynamic systems. Journal of Pharmacokinetics and Biopharmaceutics, 25(4), 529-543. link ↗ |
| Εναλλακτικές ονομασίες≠ | PopPD, population PD, hierarchical PD modeling | PBPK, PBPK modeling |
| Συναφείς | 3 | 3 |
| Σύνοψη≠ | Population pharmacodynamic (PopPD) modeling integrates pharmacokinetics with individual dose-response relationships across patient populations to characterize drug efficacy and tolerability. Pioneered by Lewis Sheiner and colleagues, PopPD accounts for inter-individual variability in drug effects and enables rational dose optimization and response prediction. | PBPK is a mechanistic modeling framework that uses physiological parameters, tissue properties, and drug-specific attributes to predict drug concentration time profiles in the body. Developed rigorously in the 1990s by researchers including Nestorov, PBPK integrates anatomy, biochemistry, and kinetics to enable rational drug development, bridging in vitro data to clinical outcomes. |
| ScholarGateΣύνολο δεδομένων ↗ |
|
|